Scale -


  • Quarterly Revenue is 304 Rs Cr; Continuous Growth over 3 Quarters; in Top Quartile
  • Revenue is 811 Rs Cr; in Top Quartile
  • Ebitda is 76.3 Rs Cr; in Top Quartile; Annual Decline is -47 %
  • PAT is 21.21 Rs Cr; in Top Quartile; 5 Year CAGR is 92 %; Annual Decline is -78 %
  • Quarterly Ebitda is 14 Rs Cr; in Top Quartile
  • PBT is 2.65 Rs Cr; Annual Decline is -78 %

Profitability -


  • PAT Margin is 2.61 %; 5 Year CAGR is 75 %; Annual Decline is -75 %; Continuous Decline over 3 years
  • PBDIT Margin is 9.4 %; Annual Decline is -40 %; Continuous Decline over 3 years
  • Quarterly Profit margin is 1 %; in Bottom Quartile

Return -


  • ROCE is 2.5 %; Annual Decline is -68 %; Continuous Decline over 3 years
  • ROA is 1.07 %; Annual Decline is -82 %; Continuous Decline over 3 years
  • ROE is 1.59 %; Annual Decline is -80 %; Continuous Decline over 3 years
  • Asset Turnover is 45 %; Annual Decline is -21 %; Continuous Decline over 3 years; in Bottom Quartile

Efficiency -


  • Operating cash flow is 101 Rs Cr; Annual Growth is 427 %; in Top Quartile
  • Current Ratio is 2.45; Continuous Decline over 3 years
  • Quick Ratio is 1.53; Continuous Decline over 3 years

Solvancy -


  • Contingent Liabilities is 0 Rs Cr; Annual Decline is -100 %; in Top Quartile
  • Debt/Equity is 0.28; Annual Growth is 100 %; Continuous Growth over 3 years
  • Long term Debt is 328 Rs Cr; Annual Growth is 149 %; Continuous Growth over 3 years; in Top Quartile
  • Total Debt is 357 Rs Cr; Annual Growth is 105 %; Continuous Growth over 3 years; in Top Quartile

Quality -


  • Operating cashflow/ebitda is 133 %; Annual Growth is 898 %; in Top Quartile
  • Operating cashflow/PAT is 477 %; Annual Growth is 2277 %; in Top Quartile; 5 Year CAGR is -47 %
  • Current Tax/PAT is -1 %; Continuous Decline over 3 years; in Bottom Quartile
  • Exceptional Items/PBT is -31 %; in Bottom Quartile
  • Change in Inventories/Total Expenses is 8 %; Annual Growth is 247 %; Continuous Growth over 3 years; in Top Quartile

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem


Sector
Major Subsidiaries/Associates
Key Clients

Products


Products
Product details

Operations


Capacity/ Production
Key Facilities
Key Certifications
Raw materials
Recent News
Enterprise value to EBIT forward of Orchid Pharma Limited – BSE:ORCHPHARMA
Orchid Pharma Signs Agreement with Libra to Expand Exblifep Sales Across Nine Latin American Markets
NCLT sanctions Orchid Pharma-Dhanuka Labs merger
Orchid Pharma Licenses Antibiotic to Libra for Latin America
Orchid Pharma Limited Estimates – NSE:ORCHPHARMA
Orchid Pharma Limited Expands Exblifep (Cefepime/Enmetazobactam) into Latin America Through Licensing and Supply Agreement with Laboratorio Libra S.A
Orchid Pharma ORCHPHARMA Exblifep Latin America Deal
Orchid Pharma signs $80m Latin America deal for Exblifep with Libra
Stocks To Watch Today: Sun Pharma, Schaeffler India, Infosys, Titan And Orchid Pharma
Orchid Pharma Board Approves Enabling Resolution to Raise Rs 600 Crore
Orchid Pharma board approves fund-raising plan for up to Rs. 600 crore
Orchid Pharma to Explore Raising ?600 Crore
Orchid Pharma ORCHPHARMA Q2 FY27 Reg 74(5) Certificate Filed